M&A Deal Summary

Genzyme Acquires AnorMED

On October 17, 2006, Genzyme acquired life science company AnorMED for 580M USD

Acquisition Highlights
  • This is Genzyme’s 8th transaction in the Life Science sector.
  • This is Genzyme’s 5th largest (disclosed) transaction.
  • This is Genzyme’s 1st transaction in Canada.
  • This is Genzyme’s 1st transaction in British Columbia.

M&A Deal Summary
Date 2006-10-17
Target AnorMED
Sector Life Science
Buyer(s) Genzyme
Deal Type Add-on Acquisition
Deal Value 580M USD

Target

AnorMED

Langley, British Columbia, Canada
AnorMED is a chemistry-based biopharmaceutical company focused on the discovery, development and commercialization of new therapeutic products in the areas of hematology, oncology and HIV, based on the Company's research into chemokine receptors.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Genzyme

Cambridge, Massachusetts, United States
Category Company
Founded 1981
Sector Life Science
DESCRIPTION
Genzyme laboratory in Framingham, Massachusetts.
Genzyme laboratory in Framingham, Massachusetts.

Genzyme is a global biotech company. Genzyme's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and immune disease. Genzyme was formed in 1981 and is based in Cambridge, Massachusetts.

DEAL STATS #
Overall 10 of 12
Sector (Life Science) 8 of 9
Type (Add-on Acquisition) 9 of 10
State (British Columbia) 1 of 1
Country (Canada) 1 of 1
Year (2006) 1 of 1
Size (of disclosed) 5 of 9
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2005-07-01 Bone Care International

Middleton, Wisconsin, United States

Bone Care International, Inc. is a bio-pharmaceutical company.

Buy $719M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2007-10-23 Bioenvision

New York City, New York, United States

Biotechnology company focused on the development and commercialization of drugs to treat oncology and infectious diseases.

Buy $345M
Mergr

Product

Company

Legal